Northern Trust’s Lexeo Therapeutics LXEO Stock Holding History

Northern Trust’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.83M	Buy	493,666 +36,614	+8%	+$259K	﹤0.01%	2782
2025 Q4	$4.54M	Buy	457,052 +220,599	+93%	+$2.01M	﹤0.01%	2530
2025 Q3	$1.57M	Buy	236,453 +35,667	+18%	+$172K	﹤0.01%	3165
2025 Q2	$807K	Sell	200,786 -5,307	-3%	-$17.5K	﹤0.01%	3494
2025 Q1	$715K	Sell	206,093 -8,191	-4%	-$36.3K	﹤0.01%	3417
2024 Q4	$1.41M	Buy	214,284 +14,185	+7%	+$112K	﹤0.01%	3212
2024 Q3	$1.81M	Buy	200,099 +105,192	+111%	+$1.25M	﹤0.01%	3063
2024 Q2	$1.52M	Buy	94,907 +12,806	+16%	+$186K	﹤0.01%	3055
2024 Q1	$1.29M	Buy	82,101 +66,512	+427%	+$1.04M	﹤0.01%	3198
2023 Q4	$209K	Buy	+15,589	New	+$194K	﹤0.01%	3883

Other funds holding LXEO

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust's LXEO Position: Q1 2026 in Review

Northern Trust increased its Lexeo Therapeutics (LXEO) stake by 8% in Q1 2026, buying an estimated $259K and bringing the position to 493,666 shares worth $2.83M. The position accounts for ﹤0.01% of the portfolio, ranked #2782.

Northern Trust first reported a position in LXEO in Q4 2023 and has held it in 10 quarters since. The position peaked at $4.54M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

Northern Trust held 493,666 shares of Lexeo Therapeutics worth $2.83M as of Q1 2026.
Northern Trust bought 36,614 Lexeo Therapeutics shares in Q1 2026, an estimated $259K.
Lexeo Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2782 holding.
Northern Trust first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 10 quarters since.
Northern Trust's Lexeo Therapeutics position peaked at $4.54M in Q4 2025.
139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.